were observed in rats. Dogs produced only one metabolite, MNTX-3-glucuronide (M9). In conclusion, MNTX was not extensively metabolized in humans. Conversion to methyl-6-naltrexol isomers (M4 and M5) and MNTX-3-sulfate (M2) were the primary pathways of metabolism in humans. MNTX was metabolized to a higher extent in mice than in rats, dogs, and humans. Glucuronidation was a major metabolic pathway in mice, rats and dogs, but not in humans. Overall, the data suggested species differences in the metabolism of MNTX.
DMD #31179

Introduction
Methylnaltrexone bromide (MNTX, (5α)-17-(cyclopropylmethyl)-3,14-dihydroxy-17-methyl-4,5-epoxymorphinanium-17-ium-6-one) is a selective peripherally acting mu-opioid receptor antagonist. In vitro testing shows that MNTX binds to mu receptors at 8-fold higher potency than to kappa receptors and it does not interact with delta receptors. MNTX is a quaternary derivative of the opioid antagonist naltrexone (Brown and Goldberg, 1985) . The addition of the methyl group to naltrexone at the nitrogen atom forms MNTX, an inherently positively charged compound with greater polarity and lower lipid solubility than naltrexone. MNTX is restricted from crossing the blood-brain-barrier in animals at pharmacologically relevant doses (Brown and Goldberg, 1985; Yuan et al., 1996; Yuan et al., 1998) . MNTX prevents the inhibition of opioidinduced gut contractions in guinea pig ileum (Chen and Rosow, 2007) . Studies in a variety of animal species have shown that peripherally or systemically administered MNTX blocks the peripherally mediated side effects of opioids, particularly their inhibition of gastrointestinal motility, with no effect on centrally mediated analgesia or opioid tolerance.
MNTX reverses the opioid-induced delay in both gastric emptying and transit time without affecting analgesia in human volunteers (Yuan et al., 1996; Yuan et al., 2002) . In a randomized placebo-controlled study in long-term methadone users, MNTX was shown to induce laxation (Yuan et al., 2000) . In a phase 3 clinical trial, subcutaneous injection of MNTX rapidly induced laxation in patients with advanced illness who were receiving opioid therapy for pain. In addition, MNTX treatment did not affect central analgesia or lead to opioid withdrawal (Thomas et al., 2008) . RELISTOR ® (methylnaltrexone bromide) is currently approved in the US as an DMD #31179 injectable medication for the treatment of opioid-induced constipation in patients with advanced illness who are receiving palliative care, when response to laxative therapy has not been sufficient, and is approved elsewhere around the world for similar indications.
A limited number of studies have been reported in the literature on the metabolism of MNTX in animals and humans (Kotake et al., 1989; Misra et al., 1987; Murphy et al., 2001; Kim et al., 1989 ). The focus of those studies was to evaluate the potential uptake into the brain in rats and the extent of demethylation in laboratory animals and humans. The data showed that the penetration of MNTX into the rat brain was restricted. MNTX was not demethylated to any significant extent in humans. Mice and rats had a slightly higher capability to N-demethylate MNTX than dogs or humans. The present studies were performed to determine the metabolism of radiolabeled MNTX in mice, rats, dogs and humans following intravenous administration. and reconstituted in CD 3 OD for NMR spectroscopic analysis.
Methyl-6α-naltrexol and methyl-6β-naltrexol, the reference standards for MNTX metabolites M4 and M5, respectively, were synthesized by the method of Malspeis for naltrexone (Malspeis et al., 1975) . Briefly, MNTX (100 mg) was dissolved in 95% ethanol (5 mL), and the alcoholic solution was cooled in an ice bath. Sodium borohydride (25 mg) was slowly added with stirring, and the mixture was brought to room temperature and stirred for an additional 2 h. The solvent was evaporated under a nitrogen stream in a TurboVap LV evaporator (Caliper Life Sciences) and the residue was dissolved in water (2 mL). After acidification with 1N HCl, aliquots of the solution were injected onto an HPLC column and the products were isolated after UV detection using the HPLC method described later. , 5, 15, 30, and 45 min, and 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, 48, 72, 96 , and 120 h post-dose. Urine samples were collected at 0-24, 24-48, 48-72, 72-96, 96-120 and 120-144 
High Performance Liquid Chromatography (HPLC). A Waters model 2695 HPLC system
(Waters Corp.) with a built-in autosampler was used for analysis. Separations were accomplished on a Luna C18(2) column (250 x 4.6 mm, 5 μm) (Phenomenex, Torrance, CA).
The sample chamber in the autosampler was maintained at 4°C, while the column was at 40°C.
The mobile phase consisted of 0.05% trifluoroacetic acid (TFA) in water (A, v/v) and 0.05% TFA in methanol (B, v/v) and was delivered at 0.6 mL/min. The linear HPLC gradient started at 10% B and increased to 20% over 25 minutes and then increased to 30% over 5 minutes.
Flo-One analytical software (version 3.65, PerkinElmer) was utilized to integrate the radioactive peaks. DataFlo software utility (beta version 0.55, PerkinElmer) was used to convert ASCII files Mass Spectrometry. Plasma extracts and urine samples were analyzed by LC/MS for metabolite characterization. Potential N-demethylation of MNTX in humans was investigated by analyzing plasma samples for naltrexone and 6β-naltrexol. The limit of detection was 6 ng/mL for naltrexone and 3 ng/mL for 6β-naltrexol. An Agilent Model 1100 HPLC system including a binary pump and diode array UV detector (Agilent Technologies, Palo Alto, CA) was used with the mass spectrometer described below. The HPLC conditions were the same as described above except that a Luna C18(2) column (250 x 2.0 mm, 5 μm) was used and the mobile phase was delivered at 0.3 mL/min. For hydrogen-deuterium exchange experiments, D 2 O was substituted for water in mobile phase A and CD 3 OD was substituted for methanol in mobile phase B.
During LC/MS sample analysis, up to 10 min of the initial flow was diverted away from the mass spectrometer prior to evaluation of metabolites. For some LC/MS analyses, radioactivity was simultaneously monitored with a Radiomatic 150TR radioactivity flow detector (PerkinElmer) to estimate retention times of radiolabeled metabolites in LC/MS data. Flow from the HPLC was split between the mass spectrometer and radioactivity detector such that the flow rate to the mass spectrometer was approximately 100 μL/min. C gHMBC NMR data were acquired. All spectra were referenced to the signal of CHD 2 OD at 3.32 ppm in the 1 H spectra and 48.1 ppm in the 13 C spectra. All spectra were measured at room temperature.
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RESULTS
Human study
Six male subjects were enrolled in this study to evaluate the pharmacokinetics of MNTX, total radioactivity in plasma, to determine the urinary and fecal recovery of radioactivity and to characterize the metabolite profiles of MNTX. Each subject was administered a single 0.3 mg/kg (100 μCi) dose of [ 14 C]MNTX as a one-minute intravenous infusion and all 6 subjects completed the study. Renal excretion was the primary route of elimination of total radioactivity, with mean total percent excretion of 53.6. Fecal recovery in the 0-168 hr collection period was 17.3 %. Exhaled 14 CO 2 accounted for less than 0.06% of administered radioactivity in all subjects.
Metabolite Profiles in Plasma
Metabolite profiles of extracts of plasma samples obtained from mice, rats, dogs and humans at 1 h after a single bolus IV dose of radiolabeled MNTX are shown in Figure 2 . The recovery of radioactivity into methanol was greater than 80% for all four species. The metabolites in plasma were identified based on the retention times of the synthetic reference standards, where available and LC/MS/MS fragmentation patterns. Plasma metabolites included MNTX-3-sulfate (M2, 0.7-25.0% of total plasma radioactivity), methyl-6α-naltrexol (M4, 0.6-11.9%) and methyl-6β-naltrexol (M5, 0.5-7.0%). Other minor (each less than 6% of plasma radioactivity) radioactive peaks observed in plasma extracts were not characterized due to low concentrations. Profiles determined in samples collected after 4 h are not reported due to low levels of radioactivity. Naltrexone, the N-demethylation product and its metabolite 6β-naltrexol were not detected in plasma of humans, as determined by an LC-MS method. The limit of detection was estimated to be about 6 ng/mL for naltrexone and 3 ng/mL for 6β-naltrexol. at 0.25, 1 and 4 h post-dose, respectively. MNTX-3-glucuronide (M9) was the only major metabolite in plasma, increasing over time, and represented 0-18.5% of total radioactivity in the 0.25 to 4 h period. Several other radioactive peaks (each ≤ 9% of plasma radioactivity) observed in dog plasma were not characterized due to low concentrations.
Metabolite Profiles in Urine
An average of 49.8% of the administered dose was recovered in 0-24 h human urine. The metabolite profile (Figure 4 ) of the pooled 0-24 h urine was similar to the plasma profiles in humans. MNTX represented about 82% of urinary radioactivity, while MNTX-3-sulfate (M2), methyl-6α-naltrexol (M4) and methyl-6β-naltrexol (M5) represented 4.3, 9.4 and 2.6% of urinary radioactivity, respectively. Radioactivity concentrations were too low to determine accurate metabolic profiles in samples after 24 h. In dogs, about 66.0% of the administered dose was excreted in 0-24 h urine. The metabolite profile (Figure 4 ) of the pooled 0-24 h urine was similar to the plasma profiles, and MNTX-3-glucuronide (M9) was the only metabolite in urine, representing 3.2% of total radioactivity.
Metabolite Synthesis and Characterization
MNTX. MNTX eluted at about 23 min. Mass spectral data for MNTX was obtained for comparison with its metabolites, and these data are summarized in Table 1 (Table 2) . These two synthetic epimers were differentiated by 2D NOESY spectra, which demonstrated key crosspeaks between protons H-5 and H-6 with a coupling constant of 4.9 Hz for the α-epimer (Figure 7 ), but much weaker crosspeaks between protons H-5 and H-6 with a coupling constant of 6.5 Hz for the β-epimer (data not shown). HPLC retention time and mass spectral data for synthetic methyl-6α-naltrexol and methyl-6β-naltrexol matched that for M4 and patients (Kotake et al., 1989) . Thus, potential impairment of analgesic effects of opioids through N-demethylation of MNTX in humans can be ruled out. In male rats, the metabolic pathways of MNTX were sulfation, glucuronidation, hydroxylation and methylation. MNTX was more extensively metabolized in mice than in rats, dogs and humans via glucuronidation, reduction, hydroxylation and methylation. MNTX was metabolized in dogs primarily via glucuronidation of the phenol.
There appeared to be some major differences between MNTX and naltrexone in terms of metabolism in humans and laboratory animals. In humans, in addition to the presence of 6β-naltrexol in conjugated and non-conjugated forms and conjugated naltrexone as the major metabolites, 2-hydroxy-3-O-methylnaltrexone, 3-O-methyl-6β-naltrexol and 2-hydroxy-3-Omethyl-6β-naltrexol were reported as minor or trace metabolites of naltrexone (Cone et al., 1978; Wall et al., 1981) . These metabolites were also detected in animal species along with 6α-naltrexol, 3-O-methylnaltrexone and some dealkylation products (Misra et al., 1976; Rodgers et al., 1980; Misra, 1981) , which were not observed in humans. A study in dogs showed that naltrexone was predominantly excreted as the 3-glucuronide. MNTX was metabolized via glucuronidation, hydroxylation, methylation, sulfation and carbonyl reduction in non-clinical species. Although both drugs appeared to be primarily metabolized via conjugation of the phenolic group and reduction of the ketone in humans, both 6α-and 6β-epimers of the reduced MNTX isomers, were observed for MNTX only in human plasma . Also, the extent of metabolism was much higher for naltrexone than for MNTX in humans. For example, following a subcutaneous administration of naltrexone, 6β-naltrexol represented about 40% of the administrated dose while the parent drug represented only about 10% of the administrated dose (Wall et al., 1984) , based on AUC values. In contrast to naltrexone, the carbonyl reduction metabolites M4 and M5 of MNTX represented less than 10% of total plasma radioactivity, based
on AUC values following a single IV administration of MNTX at 0.3 mg/kg.
In summary, MNTX was not extensively metabolized in humans following a single IV administration. Conversion to methyl-6-naltrexol isomers (M4 and M5) and MNTX-3-sulfate (M2) were the primary pathways of metabolism. MNTX was more extensively metabolized in mice compared to rats, dogs, and humans through glucuronidation, reduction, hydroxylation and methylation. MNTX-3-glucuronide (M9) was a major metabolite in plasma of mice, rats and dogs, but was not observed in human plasma. 2-Hydroxy-3-O-methyl MNTX glucuronide (M10) was a major metabolite in mouse plasma, but was absent in circulation of other species.
MNTX-3-sulfate (M2) was the major metabolite in rat and human plasma. However, this metabolite was not observed in other species. 2-Hydroxy-3-O-methyl MNTX (M6) was observed in the circulation of mice and rats, but was not detected in the circulation of dogs and humans. Methyl-6α-naltrexol (M4) and methyl-6β-naltrexol (M5), the reduced MNTX isomers, were both observed in human plasma. However, only methyl-6β-naltrexol (M5) was observed in the plasma of mice and rats, and neither isomer was present in dog plasma. N-Demethylation resulting in naltrexone formation was not observed in humans. These data suggested species differences in the metabolism of MNTX.
This article has not been copyedited and formatted. The final version may differ from this version. 302, 284, 227, 199, 112, 55 M2 14.0 436 438 418, 382, 356, 302, 284, 227, 199, 112, 55 M4 20.5 358 361 340, 304, 286, 229, 201, 112, 55 M5 25.5 358 361 340, 304, 286, 229, 201, 112, 55 M6 24.5 386 388 368, 332, 314, 257, 229, 112, 55 M9 12.0 532 537 356, 302, 284, 227, 199, 113, 55 M10 14.1 562 567 386, 332, 314, 257, 229, 113, 55 This article has not been copyedited and formatted. The final version may differ from this version. 
